The US Federal Trade Commission (FTC) has sought additional information and documentary material related to Pfizer's proposed acquisition of Seagen Inc , Seagen said on Friday.
The antitrust agency sent the requests separately to both the companies, a regulatory filing said.
Pfizer struck a $43 billion deal in March to acquire Seagen and its targeted cancer therapies, to counter the fall in COVID-related sales and generic competition for some top-selling drugs.
The recent scrutiny by the antitrust agency to block Amgen's $27.8 billion deal to buy Horizon Therapeutics has made investors jittery around the Pfizer-Seagen deal as well.
Seagan continues to expect its merger with Pfizer will be completed in late 2023 or early 2024, it said in the filing.
https://finance.yahoo.com/news/1-us-ftc-seeks-additional-214610644.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.